# Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

> **NCT00023881** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00023881
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-07-02
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2018-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023881, "Bortezomib in Treating Patients With Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00023881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*